Lane Nancy E
Aging Center, Medicine and Rheumatology, University of California, Davis Medical Center, Sacramento, CA 95817, USA.
Am J Obstet Gynecol. 2006 Feb;194(2 Suppl):S3-11. doi: 10.1016/j.ajog.2005.08.047.
Osteoporosis, a major public health problem, is becoming increasingly prevalent with the aging of the world population. Osteoporosis is a skeletal disorder characterized by compromised bone strength, which predisposes the individual to an increased risk of fractures of the hip, spine, and other skeletal sites. The clinical consequences and economic burden of this disease call for measures to assess individuals who are at high risk to allow for appropriate intervention. Many risk factors are associated with osteoporotic fracture, including low peak bone mass, hormonal factors, the use of certain drugs (eg, glucocorticoids), cigarette smoking, low physical activity, low intake of calcium and vitamin D, race, small body size, and a personal or a family history of fracture. All of these factors should be taken into account when assessing the risk of fracture and determining whether further treatment is required. Because osteoporotic fracture risk is higher in older women than in older men, all postmenopausal women should be evaluated for signs of osteoporosis during routine physical examinations. Radiologic laboratory assessments of bone mineral density generally should be reserved for patients at highest risk, including all women over the age of 65, younger postmenopausal women with risk factors, and all postmenopausal women with a history of fractures. The evaluation of biochemical markers of bone turnover has been useful in clinical research. However, the predictive factor of these measurements is not defined clearly, and these findings should not be used as a replacement for bone density testing. Together, clinical assessment of osteoporotic risk factors and objective measures of bone mineral density can help to identify patients who will benefit from intervention and, thus, can potentially reduce the morbidity and mortality associated with osteoporosis-associated fractures in this population.
骨质疏松症是一个主要的公共卫生问题,随着世界人口老龄化,其发病率日益上升。骨质疏松症是一种骨骼疾病,其特征是骨强度受损,这使个体易患髋部、脊柱和其他骨骼部位骨折的风险增加。这种疾病的临床后果和经济负担要求采取措施评估高危个体,以便进行适当干预。许多风险因素与骨质疏松性骨折有关,包括低峰值骨量、激素因素、使用某些药物(如糖皮质激素)、吸烟、体力活动不足、钙和维生素D摄入不足、种族、身材矮小以及个人或家族骨折史。在评估骨折风险和确定是否需要进一步治疗时,应考虑所有这些因素。由于老年女性骨质疏松性骨折的风险高于老年男性,所有绝经后女性在常规体检时都应评估是否有骨质疏松的迹象。骨密度的放射学实验室评估通常应保留给高危患者,包括所有65岁以上的女性、有风险因素的绝经后年轻女性以及所有有骨折史的绝经后女性。骨转换生化标志物的评估在临床研究中很有用。然而,这些测量的预测因素尚未明确界定,这些结果不应作为骨密度检测的替代方法。骨质疏松风险因素的临床评估和骨密度的客观测量相结合,有助于识别将从干预中受益的患者,从而有可能降低该人群中与骨质疏松相关骨折相关的发病率和死亡率。